Opinion|Videos|January 13, 2025

Decision Points for Using CAR T-Cell Therapy in Early Lines of Treatment

Author(s)Ajai Chari, MD, Anupama Kumar, MD, Darren Pan, MD

Panelists discuss how, when considering earlier lines of CAR T-cell therapy for relapsed/refractory multiple myeloma, key institutional factors include patient fitness/age, cytogenetic risk status, prior therapy response duration, and BCMA expression levels. Manufacturing timelines, financial considerations, and center-specific outcomes data also influence timing decisions. For patients receiving early-line CAR T therapy, subsequent treatment options typically focus on novel agent combinations or clinical trials exploring additional cellular therapies, with choices guided by response duration to CAR T and the patient’s individual disease characteristics and treatment goals.

Episodes in this series

EP. 1 Introduction and CAR-T Therapy in Earlier Lines of Treatment for R/R Multiple Myeloma

EP. 1 Introduction and CAR-T Therapy in Earlier Lines of Treatment for R/R Multiple Myeloma

EP. 2 Decision Points for Using CAR T-Cell Therapy in Early Lines of Treatment

EP. 2 Decision Points for Using CAR T-Cell Therapy in Early Lines of Treatment

EP. 3 Second-Line Treatment for R/R Multiple Myeloma: Who Is the “Right Patient”?

EP. 3 Second-Line Treatment for R/R Multiple Myeloma: Who Is the “Right Patient”?

EP. 4 Referral Process for CAR T-Cell Therapy: Initial Contact Through Patient Evaluation and Selection

EP. 4 Referral Process for CAR T-Cell Therapy: Initial Contact Through Patient Evaluation and Selection

EP. 5 CAR T-Cell Therapy: CAR T-Cell therapy Process and Bridging Therapy

EP. 5 CAR T-Cell Therapy: CAR T-Cell therapy Process and Bridging Therapy

EP. 6 Co-Management and Co-Monitoring of Patients Receiving CAR T-Cell Treatment: Transitions Between the Academic and Community Centers

EP. 6 Co-Management and Co-Monitoring of Patients Receiving CAR T-Cell Treatment: Transitions Between the Academic and Community Centers

EP. 7 Management of Adverse Events of Special Interest in Patients Receiving CAR -T-Cell Therapy for R/R Multiple Myeloma: Diarrhea, Guillain-Barrée Syndrome, Parkinson’s Disease, and Secondary Malignancies

EP. 7 Management of Adverse Events of Special Interest in Patients Receiving CAR -T-Cell Therapy for R/R Multiple Myeloma: Diarrhea, Guillain-Barrée Syndrome, Parkinson’s Disease, and Secondary Malignancies

EP. 8 Example of Successful Collaboration with a Referring Community Practice

EP. 8 Example of Successful Collaboration with a Referring Community Practice

EP. 9 CAR T-Cell Therapy in Multiple Myeloma: Lessons Learned and Key Takeaways

EP. 9 CAR T-Cell Therapy in Multiple Myeloma: Lessons Learned and Key Takeaways

Video content above is prompted by the following:

What are the key factors that influence your institution’s decision to utilize CAR T therapy in earlier lines of treatment for relapsed/refractory multiple myeloma?
If you choose to utilize CAR T in earlier lines of therapy, what might you do next and why?

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Related to this article

Rheumatoid arthritis RA in an autoimmune disease faultry activated b cells emitting antibodies which attack the joints causes inflammation front view 3d illustration. with copy space image | Image Credit © vxnaghiyev - stock.adobe.com

September 23rd, 2026

Optimizing Cilta-Cel Sequencing and Community Coordination in Multiple Myeloma

Hematologic specialists discussed where ciltacabtagene autoleucel fits in the treatment paradigm at first relapse and beyond in multiple myeloma.

Hans C. Lee, MD, discussed how community oncologists with limited access to MRD testing can think about the new IMS/IMWG definition of cure in myeloma.

September 27th, 2026

Applying the IMS/IMWG Definition of Cure in Community Myeloma Practice

Hans C. Lee, MD, discussed how community oncologists with limited access to MRD testing can think about the new IMS/IMWG definition of cure in myeloma.

Hans C. Lee, MD, discussed how he monitors patients with multiple myeloma who achieve deep, sustained MRD negativity after coming off therapy.

September 26th, 2026

Managing Sustained MRD Negativity After Multiple Myeloma Therapy Ends

Hans C. Lee, MD, discussed how he monitors patients with multiple myeloma who achieve deep, sustained MRD negativity after coming off therapy.

“[W]e should strive to increase the [number] of patients…who enjoy long-term disease-free survival and possibly cure,” said Meletios Dimopoulos, MD.

September 25th, 2026

Targeted Agents, Amyloidosis, and Defining a Cure in Plasma Cell Disorders

“[W]e should strive to increase the [number] of patients…who enjoy long-term disease-free survival and possibly cure,” said Meletios Dimopoulos, MD.

Sustained MRD Negativity With DVRd Signals Long-Term Survival in NDMM

September 25th, 2026

Sustained MRD Negativity With DVRd Signals Long-Term Survival in NDMM

Pieter Sonneveld, MD, PhD, explained how sustained MRD negativity with DVRd in the PERSEUS trial may guide long-term outcome counseling in multiple myeloma.

Updated NCCN Guidelines for multiple myeloma add a dedicated MRD testing framework and expand recommended MRD assessment timepoints.

September 18th, 2026

NCCN Guidelines Strengthen MRD Testing Recommendations in Multiple Myeloma

Updated NCCN Guidelines for multiple myeloma add a dedicated MRD testing framework and expand recommended MRD assessment timepoints.

Trending on CancerNetwork

Acting on a HER2 Result and Navigating Access to Therapy

The Case for Frontline Zongertinib in HER2-Mutant NSCLC

Subcutaneous Pembrolizumab Approved in Japan for All Tumor Indications

Emerging Endocrine Doublets and Serial ESR1 Testing in HR+/HER2− mBC

Durvalumab Plus Enfortumab Vedotin Earns FDA Priority Review in MIBC